MX356278B - Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa. - Google Patents

Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa.

Info

Publication number
MX356278B
MX356278B MX2015003657A MX2015003657A MX356278B MX 356278 B MX356278 B MX 356278B MX 2015003657 A MX2015003657 A MX 2015003657A MX 2015003657 A MX2015003657 A MX 2015003657A MX 356278 B MX356278 B MX 356278B
Authority
MX
Mexico
Prior art keywords
inhibitor
pharmaceutical combination
phosphatidylinositol
treatment
aromatase inhibitor
Prior art date
Application number
MX2015003657A
Other languages
English (en)
Other versions
MX2015003657A (es
Inventor
Huang Xizhong
Goldbrunner Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015003657A publication Critical patent/MX2015003657A/es
Publication of MX356278B publication Critical patent/MX356278B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende un compuesto derivado de 2-carboxamida cicloamino urea de fórmula (I) y al menos un inhibidor de aromatasa para el tratamiento de cáncer; a los usos de dichas combinaciones en el tratamiento de cáncer; y a un método para tratar animales de sangre caliente que incluyen humanos que padecen cáncer mediante la administración a dicho animal que necesita dicho tratamiento de una dosis eficaz de un compuesto derivado de 2-carboxamida cicloamino urea de fórmula (I), en combinación con al menos un inhibidor de aromatasa.
MX2015003657A 2012-09-20 2013-09-18 Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa. MX356278B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261703533P 2012-09-20 2012-09-20
US201261708070P 2012-10-01 2012-10-01
PCT/US2013/060292 WO2014047109A1 (en) 2012-09-20 2013-09-18 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor

Publications (2)

Publication Number Publication Date
MX2015003657A MX2015003657A (es) 2015-06-05
MX356278B true MX356278B (es) 2018-05-22

Family

ID=49263471

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003657A MX356278B (es) 2012-09-20 2013-09-18 Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa.

Country Status (21)

Country Link
US (1) US9532982B2 (es)
EP (1) EP2897644B1 (es)
JP (1) JP6212563B2 (es)
KR (1) KR102220965B1 (es)
CN (1) CN104661681B (es)
AU (1) AU2013318205B2 (es)
BR (1) BR112015004152A2 (es)
CA (1) CA2880506C (es)
CY (1) CY1120984T1 (es)
DK (1) DK2897644T3 (es)
ES (1) ES2686689T3 (es)
HR (1) HRP20181413T1 (es)
HU (1) HUE040520T2 (es)
IN (1) IN2015DN00735A (es)
LT (1) LT2897644T (es)
MX (1) MX356278B (es)
PL (1) PL2897644T3 (es)
PT (1) PT2897644T (es)
RU (1) RU2651023C2 (es)
SI (1) SI2897644T1 (es)
WO (1) WO2014047109A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948351C (en) * 2014-05-09 2023-10-03 Memorial Sloan-Kettering Cancer Center Biomarkers for response to pi3k inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8809001A1 (es) * 2007-12-20 2009-07-23 Novartis Ag Compuestos organicos
EP2238134A2 (en) * 2007-12-20 2010-10-13 Novartis AG Bis-thiazole derivatives, process for their preparation and their use as medicaments
US20110178070A1 (en) * 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas

Also Published As

Publication number Publication date
IN2015DN00735A (es) 2015-07-10
PL2897644T3 (pl) 2018-11-30
HUE040520T2 (hu) 2019-03-28
US9532982B2 (en) 2017-01-03
CN104661681A (zh) 2015-05-27
EP2897644B1 (en) 2018-06-06
HRP20181413T1 (hr) 2018-10-19
ES2686689T3 (es) 2018-10-19
CA2880506A1 (en) 2014-03-27
BR112015004152A2 (pt) 2017-07-04
KR20150056778A (ko) 2015-05-27
WO2014047109A1 (en) 2014-03-27
RU2651023C2 (ru) 2018-04-18
JP6212563B2 (ja) 2017-10-11
MX2015003657A (es) 2015-06-05
CN104661681B (zh) 2018-07-03
LT2897644T (lt) 2018-09-25
PT2897644T (pt) 2018-10-16
AU2013318205B2 (en) 2016-05-19
AU2013318205A1 (en) 2015-02-26
CY1120984T1 (el) 2019-12-11
EP2897644A1 (en) 2015-07-29
KR102220965B1 (ko) 2021-02-26
US20150231124A1 (en) 2015-08-20
DK2897644T3 (en) 2018-09-10
CA2880506C (en) 2021-04-20
JP2015532927A (ja) 2015-11-16
SI2897644T1 (sl) 2018-10-30
RU2015111171A (ru) 2016-11-10

Similar Documents

Publication Publication Date Title
MX2015014596A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer.
EA201290919A1 (ru) Индазольные соединения и их применение
BR112015009168A2 (pt) composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
PH12016502352A1 (en) Pharmaceutical composition
MX2013003638A (es) Tratamiento en combinacion para rosacea.
EA201491500A1 (ru) Способы лечения фиброза
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
MX366140B (es) Derivados de urea de piperidinas.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
PH12014502065A1 (en) Vesicular formulations
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
EA201201404A1 (ru) Триазолы как ингибиторы кбв (кинезин-белок веретена)
MX356278B (es) Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa.
MX2014004559A (es) Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas.

Legal Events

Date Code Title Description
FG Grant or registration